Skip to Content

Guidelines Home

Introduction

1. Abstract

2. Executive Summary

3. Background

4. Treatment

5. Special Medical Considerations

6. Treatment Considerations

7. Classes of Medications

8. Emergency Guidelines

9. Conclusions

10. Acknowledgments

11. Disclosures

12. Authors’ Contact Information

Brief Outlines

Guidelines QR Codes

FOP Doctors and Specialists

Link to IFOPA Website

Link to Clinical Trials

Prepare for Clinical Trials

Clinical Trial Committee Chair

FOP Doctors and Specialists

Link to Clinical Trials

FOP Publications

FOP Presentations

Member Login

Guidelines Home

Introduction

1. Abstract

2. Executive Summary

3. Background

4. Treatment

5. Special Medical Considerations

6. Treatment Considerations

7. Classes of Medications

8. Emergency Guidelines

9. Conclusions

10. Acknowledgments

11. Disclosures

12. Authors’ Contact Information

Brief Outlines

Guidelines QR Codes

FOP Doctors and Specialists

Link to IFOPA Website

Link to Clinical Trials

Prepare for Clinical Trials

Clinical Trial Committee Chair

FOP Doctors and Specialists

Link to Clinical Trials

FOP Publications

FOP Presentations

Member Login

Folder: About Us

Folder: Treatment Guidelines

Guidelines Home

Introduction

1. Abstract

2. Executive Summary

3. Background

4. Treatment

5. Special Medical Considerations

6. Treatment Considerations

7. Classes of Medications

8. Emergency Guidelines

9. Conclusions

10. Acknowledgments

11. Disclosures

12. Authors’ Contact Information

Brief Outlines

Guidelines QR Codes

Folder: Patients

FOP Doctors and Specialists

Link to IFOPA Website

Link to Clinical Trials

Prepare for Clinical Trials

Folder: Industry

Clinical Trial Committee Chair

Folder: Healthcare Providers

FOP Doctors and Specialists

Link to Clinical Trials

FOP Publications

FOP Presentations

Member Login

MEDIA

Press Releases

Most Recent – 2025

Oct 2025 – Published FOP Guidelines Letter
Oct 2025 – Published FOP Guidelines
July 2024 – Updated Treatment Guidelines

Archive News – 2024

May 2024 – ICC Statement on Off Label Medications
March 2024 – ICC Statement on Off Label Medications

Archive News – 2023

August 2023 – ICC Statement on Palovarotene
Augosto 2023 – Spanish Statement on Palovarotene

Archive News – 2022

May 2022 – Updated Treatment Guidelines
May 2022 – Updated Coronavirus (COVID-19) Vaccine Recommendations
January 2022 – Updated Treatment Guidelines
January 2022 – Updated Coronavirus (COVID-19) Vaccine Recommendations

Archive News – 2021

August, 2021 – Updated Treatment Guidelines
April 12, 2021 – Updated Treatment Guidelines
March 18, 2021 – Coronavirus (COVID-19) Vaccine recommendations

Archive News – 2020

December 30, 2020 – Updated Coronavirus (COVID-19) Precautions for FOP Families
December 2, 2020 – Editorial from the ICC regarding clinical trials
July 17, 2020 – Updated Coronavirus (COVID-19) Precautions for FOP Families
March 27, 2020 – Updated Coronavirus (COVID-19) Precautions for FOP Families
March 18, 2020 – Revised Coronavirus (COVID-19) Precautions for FOP Families
March 16, 2020 – Coronavirus (COVID-19) Precautions for FOP Families

Archive News 2019

March, June, 2019 – Updated Treatment Guidelines
May 2019, ICC’s statement on FOPCon

Archive News – 2018

September 2018, publication from ICC regarding special clinical trial considerations in FOP
March 2018, Announcement of ICC on IFOPA website

Join our mailing list

Sign up to receive updates from us.

© 2025 The International Clinical Council (ICC) on Fibrodysplasia Ossificans Progressiva (FOP).